Blue Crest Capital Management LTD Biomarin Pharmaceutical Inc Transaction History

Blue Crest Capital Management LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $613,728 - $958,357	-7,715 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $142,740 - $193,700	2,000 Added 35.0%	7,715 $652,000
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $38,562 - $51,822	-600 Reduced 9.5%	5,715 $483,000
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $168,500 - $212,775	2,500 Added 65.53%	6,315 $426,000
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $306,535 - $358,228	3,815 New	3,815 $327,000
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $215,095 - $284,691	-2,684 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $42,639 - $47,996	454 Added 20.36%	2,684 $260,000
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $169,502 - $220,836	2,230 New	2,230 $210,000
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $431,823 - $508,660	-5,347 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $430,968 - $507,697	5,347	5,347 $498,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.